MediPrint Ophthalmics, a San Diego, CA-based clinical stage eye care pharmaceutical company, raised $2.5M in Series A funding.
The backers were not disclosed.
Led by Dan Myers, CEO, MwdiPrint Ophthalmics is a clinical stage eye care pharmaceutical company focused on enhancing vision for life by developing and commercializing a proprietary contact lens based ocular drug delivery portfolio. The company is currently advancing its lead asset, a complete glaucoma treatment, to the clinic while continuing to build out its product portfolio for dry eye and for allergy, and subsequently for other anterior and posterior segment conditions.
MediPrint Ophthalmics intends to use the funds to support the upcoming Phase 2b clinical study along with the end of Phase 2 meeting with the FDA for its lead glaucoma asset also advance other products to clinical trials, most notably the dry eye asset.